We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-3.45%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$334M
AUM Growth
-$21.5M
Cap. Flow
+$1.64M
Cap. Flow %
0.49%
Top 10 Hldgs %
52.03%
Holding
83
New
4
Increased
23
Reduced
12
Closed
11

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$3.77M
2
IPSC icon
Century Therapeutics
IPSC
+$3.65M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$2.89M
4
PRQR icon
ProQR Therapeutics
PRQR
+$2.88M
5
RVMD icon
Revolution Medicines
RVMD
+$2.41M

Top Sells

Rank Stock Value
1
FATE icon
Fate Therapeutics
FATE
+$5.56M
2
ETNB
89bio
ETNB
+$4.13M
3
FSTX
F-star Therapeutics, Inc. Common Stock
FSTX
+$3.65M
4
BHVN icon
Biohaven
BHVN
+$2.51M
5
VKTX icon
Viking Therapeutics
VKTX
+$2.09M

Sector Composition

Rank Sector Weight
1 Healthcare 81.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
26
Adicet Bio
ACET
$74.2M
$4.59M 1.38%
49,816
+10,344
+26% +$1.3M
IPSC icon
27
Century Therapeutics
IPSC
$343M
$4.54M 1.36%
1,307,407
+832,040
+175% +$3.65M
APLS
28
DELISTED
Apellis Pharmaceuticals
APLS
$3.81M 1.14%
57,746
-25,700
-31% -$1.48M
ALEC icon
29
Alector
ALEC
$203M
$3.67M 1.1%
592,438
+60,000
+11% +$488K
ARAY icon
30
Accuray
ARAY
$33.8M
$3.63M 1.09%
1,222,358
– –
MDWD icon
31
MediWound
MDWD
$184M
$3.43M 1.03%
257,653
+53,571
+26% +$676K
BHVN icon
32
Biohaven
BHVN
$2.17B
$3.22M 0.97%
235,613
-157,500
-40% -$2.51M
RCUS icon
33
Arcus Biosciences
RCUS
$3.61B
$3.2M 0.96%
175,217
+33,000
+23% +$631K
AXGN icon
34
Axogen
AXGN
$2.38B
$3.14M 0.94%
332,103
– –
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$2.74M 0.82%
73,600
– –
BCYC
36
Bicycle Therapeutics
BCYC
$278M
$2.6M 0.78%
122,200
– –
AUTL
37
Autolus Therapeutics
AUTL
$532M
$2.16M 0.65%
1,176,150
– –
MRSN
38
DELISTED
Mersana Therapeutics
MRSN
$2.1M 0.63%
20,435
+3,896
+24% +$547K
LKFT
39
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$2.04M 0.61%
52,675
– –
PRQR icon
40
ProQR Therapeutics
PRQR
$268M
$2M 0.6%
+940,582
New +$2.88M
VIGL
41
DELISTED
Vigil Neuroscience
VIGL
$1.69M 0.51%
172,308
+3,462
+2% +$38.9K
KURA icon
42
Kura Oncology
KURA
$824M
$1.34M 0.4%
109,784
-35,000
-24% -$437K
ITOS
43
DELISTED
iTeos Therapeutics
ITOS
$1.34M 0.4%
98,560
– –
THRX
44
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$1.16M 0.35%
131,025
+49,166
+60% +$483K
LRMR icon
45
Larimar Therapeutics
LRMR
$436M
$1.07M 0.32%
236,873
-236,263
-50% -$1.23M
ORIC icon
46
Oric Pharmaceuticals
ORIC
$1.34B
$971K 0.29%
170,326
-93,911
-36% -$491K
ATXS
47
DELISTED
Astria Therapeutics
ATXS
$929K 0.28%
+69,883
New +$945K
STIM icon
48
Neuronetics
STIM
$157M
$913K 0.27%
313,717
– –
BWAY
49
Brainsway
BWAY
$628M
$832K 0.25%
947,962
+507,962
+115% +$512K
KROS icon
50
Keros Therapeutics
KROS
$211M
$827K 0.25%
19,361
-13,639
-41% -$689K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q1 2023 Portfolio in Review

As of Q1 2023, DAFNA Capital Management held 83 positions worth $334M, down 6.1% from $355M the previous quarter. Its ten largest holdings account for 52% of the portfolio.

DAFNA Capital Management's Q1 2023 filing shows 4 new, 23 increased, 12 reduced and 11 closed positions. Its largest new stake was ProQR Therapeutics: 940,582 shares worth $2M. The largest sale was Fate Therapeutics, an estimated $5.56M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 82% a quarter earlier.

  • DAFNA Capital Management's largest Q1 2023 buy was ProQR Therapeutics: 940,582 shares worth $2M.
  • DAFNA Capital Management added most to Cytokinetics in Q1 2023, an estimated $3.77M increase.
  • DAFNA Capital Management's biggest Q1 2023 reduction was Biohaven, cutting an estimated $2.51M.
  • DAFNA Capital Management fully exited Fate Therapeutics in Q1 2023, selling an estimated $5.56M.
  • DAFNA Capital Management's ten largest holdings make up 52% of its $334M portfolio in Q1 2023.
  • DAFNA Capital Management opened 4 new positions and closed 11 in Q1 2023.
  • DAFNA Capital Management's portfolio value fell 6.1% quarter-over-quarter to $334M.

Based on DAFNA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.